In AD mouse models with advanced amyloid pathology, using PD-1 immune checkpoint blockers to overcome immune tolerance induces a robust systemic IFN-γ response with subsequent recruitment of monocyte-derived macrophages (MΦ) to the brain. This evidence concerns the gene PDCD1 and Alzheimer disease.